[go: up one dir, main page]

IL171541A - Recombinant antibodies and fragments which recognize n- glycolyl- gm3 ganglioside and their use in the diagnosis and treatment of tumours - Google Patents

Recombinant antibodies and fragments which recognize n- glycolyl- gm3 ganglioside and their use in the diagnosis and treatment of tumours

Info

Publication number
IL171541A
IL171541A IL171541A IL17154105A IL171541A IL 171541 A IL171541 A IL 171541A IL 171541 A IL171541 A IL 171541A IL 17154105 A IL17154105 A IL 17154105A IL 171541 A IL171541 A IL 171541A
Authority
IL
Israel
Prior art keywords
antibody
heavy
human
fragments
murine
Prior art date
Application number
IL171541A
Other languages
English (en)
Hebrew (he)
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of IL171541A publication Critical patent/IL171541A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL171541A 2003-04-23 2005-10-23 Recombinant antibodies and fragments which recognize n- glycolyl- gm3 ganglioside and their use in the diagnosis and treatment of tumours IL171541A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20030092A CU23403A1 (es) 2003-04-23 2003-04-23 Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
PCT/CU2004/000006 WO2004094477A1 (es) 2003-04-23 2004-04-22 Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diagnostico y tratamiento de tumores.

Publications (1)

Publication Number Publication Date
IL171541A true IL171541A (en) 2013-11-28

Family

ID=40261249

Family Applications (1)

Application Number Title Priority Date Filing Date
IL171541A IL171541A (en) 2003-04-23 2005-10-23 Recombinant antibodies and fragments which recognize n- glycolyl- gm3 ganglioside and their use in the diagnosis and treatment of tumours

Country Status (31)

Country Link
EP (1) EP1623997B1 (lt)
JP (1) JP2006524194A (lt)
KR (1) KR20060006937A (lt)
CN (2) CN1809592A (lt)
AR (1) AR044076A1 (lt)
AU (1) AU2004232391B2 (lt)
BR (1) BRPI0409664A (lt)
CA (1) CA2523449C (lt)
CL (1) CL2004000843A1 (lt)
CR (1) CR8105A (lt)
CU (1) CU23403A1 (lt)
EA (1) EA008353B1 (lt)
ES (1) ES2535813T3 (lt)
GE (1) GEP20084476B (lt)
HR (1) HRP20050922A2 (lt)
HU (1) HUE025266T2 (lt)
IL (1) IL171541A (lt)
LT (1) LT5353B (lt)
LV (1) LV13427B (lt)
MX (1) MXPA05011368A (lt)
MY (1) MY144620A (lt)
NZ (1) NZ543345A (lt)
PE (1) PE20050422A1 (lt)
PL (1) PL1623997T3 (lt)
RS (2) RS20110319A3 (lt)
SI (1) SI1623997T1 (lt)
TN (1) TNSN05274A1 (lt)
TW (1) TWI343923B (lt)
UY (1) UY28289A1 (lt)
WO (1) WO2004094477A1 (lt)
ZA (1) ZA200509457B (lt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1133558E (pt) 1998-11-27 2007-01-31 Ucb Sa Composições e métodos para aumentar a mineralização óssea
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
EA029956B1 (ru) 2011-03-25 2018-06-29 Эмджен Инк. Кристаллы антител против склеростина и составы на их основе
WO2013019954A1 (en) 2011-08-04 2013-02-07 Amgen Inc. Method for treating bone gap defects
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
SG10201509629QA (en) 2011-12-28 2015-12-30 Amgen Inc Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies
CU24120B1 (es) * 2012-03-01 2015-08-27 Ct De Inmunología Molecular Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
CN104651314B (zh) * 2015-02-14 2018-06-19 百泰生物药业有限公司 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
US10711282B2 (en) 2015-11-23 2020-07-14 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
EP3397756B1 (en) 2015-12-30 2023-03-08 Novartis AG Immune effector cell therapies with enhanced efficacy
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
JP2020506700A (ja) 2017-01-31 2020-03-05 ノバルティス アーゲー 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
RU2020116579A (ru) 2017-10-25 2021-11-25 Новартис Аг Способы получения клеток, экспрессирующих химерный антигенный рецептор
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
US11466079B2 (en) 2018-03-30 2022-10-11 Amgen Inc. C-terminal antibody variants
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
KR102344948B1 (ko) * 2018-09-03 2021-12-28 세종대학교산학협력단 인간 순수만능줄기세포에 특이적인 단일클론항체 n1-a4
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN110208409A (zh) * 2019-06-05 2019-09-06 中国海洋大学 一种乳腺癌的生物标志物及其应用
US20230141511A1 (en) 2019-12-20 2023-05-11 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3
EP4076660A1 (en) 2019-12-20 2022-10-26 Novartis AG Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
AU703152B2 (en) * 1994-01-25 1999-03-18 Biogen Ma Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CA2203236A1 (en) 1994-10-28 1996-05-09 Ira Pastan Tumor-specific antibody fragments, fusion proteins, and uses thereof
WO1997002290A1 (en) * 1995-06-30 1997-01-23 Mochida Pharmaceutical Co., Ltd. ANTIFas LIGAND ANTIBODIES AND ASSAY METHOD BY USING THE SAME
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen

Also Published As

Publication number Publication date
KR20060006937A (ko) 2006-01-20
NZ543345A (en) 2009-09-25
AU2004232391A1 (en) 2004-11-04
MXPA05011368A (es) 2006-03-08
HK1183492A1 (en) 2013-12-27
RS20110319A2 (sr) 2012-02-29
CN1809592A (zh) 2006-07-26
LV13427B (en) 2006-09-20
CA2523449C (en) 2012-09-18
TWI343923B (en) 2011-06-21
CR8105A (es) 2006-05-31
LT5353B (lt) 2006-07-25
EA200501653A1 (ru) 2006-06-30
WO2004094477A1 (es) 2004-11-04
RS51853B (sr) 2012-02-29
CN103012586A (zh) 2013-04-03
EP1623997A1 (en) 2006-02-08
AU2004232391B2 (en) 2008-10-30
RS20050795A (sr) 2007-12-31
PL1623997T3 (pl) 2015-08-31
HUE025266T2 (en) 2016-02-29
CU23403A1 (es) 2009-08-04
UY28289A1 (es) 2004-11-30
GEP20084476B (en) 2008-09-10
AR044076A1 (es) 2005-08-24
HRP20050922A2 (en) 2007-03-31
RS20110319A3 (en) 2012-10-31
CA2523449A1 (en) 2004-11-04
CL2004000843A1 (es) 2005-04-15
SI1623997T1 (sl) 2015-07-31
PE20050422A1 (es) 2005-06-29
JP2006524194A (ja) 2006-10-26
ZA200509457B (en) 2006-07-26
TW200504090A (en) 2005-02-01
CN103012586B (zh) 2014-08-06
TNSN05274A1 (en) 2007-07-10
ES2535813T3 (es) 2015-05-18
LT2005101A (lt) 2006-03-27
EA008353B1 (ru) 2007-04-27
BRPI0409664A (pt) 2006-04-18
EP1623997B1 (en) 2015-04-22
MY144620A (en) 2011-10-14

Similar Documents

Publication Publication Date Title
EP1623997B1 (en) Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours
KR100919617B1 (ko) 강글리오사이드-관련 재조합 항체 및 종양의 진단 및치료에 있어서 이의 용도
US11359021B2 (en) PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP2021535744A (ja) 抗クローディン１８．２抗体及びその使用
KR20110067153A (ko) Ｍｕｃ１＊ 항체
TW200938629A (en) Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
ES2296952T3 (es) Metodo para tratar el mieloma multiple.
CN112500485A (zh) 一种抗b7-h3抗体及其应用
JP2005528884A (ja) Ｍｎ結合および細胞接着中和活性を有するヒト抗体
EP4458853A1 (en) Development of novel upar single-domain antibody
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
JP2024514855A (ja) Ｄｌｌ３に対する結合分子及びその使用
JP2022539344A (ja) 抗ｃｅａ抗体及びその応用
US20070128672A1 (en) Anti-p53 Antibodies
WO2025201517A1 (zh) 抗cd93抗体、其抗原结合片段及其应用
HK1183492B (en) Recombinant antibodies ana fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours
HK40045557A (en) An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed